- MRX-6 is a Topical, Non-Steroidal Anti-Inflammatory Cream in Phase II Trials for Eczema
- Celsus to present MRX-6 at Windover's Therapeutic Area Partnerships meeting
NEW YORK and LONDON, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company's MRX-6 treatment for eczema has been selected as one of the "Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information. Celsus management will present the project to a select group of pharmaceutical company executives at Windhover's Therapeutic Area Partnerships meeting in Boston, November 18-20.
MRX-6 is Celsus' most advanced clinical stage program developed from the Company's platform of first-in-class, synthetic, non-steroidal anti-inflammatory drugs. Topline results from the multi-center, Phase II double blind trial of MRX-6 in chronic hand eczema secondary to allergic contact dermatitis (ACD) demonstrated safety and tolerability, and clinically meaningful efficacy in this difficult to treat condition.
"It is an honor to be selected as a Top 10 Project to Watch by Elsevier," said Gur Roshwalb, Chief Executive Officer of Celsus Therapeutics. "This selection is confirmation of our recent progress as a company, and the potential for MRX-6 to treat an important unmet need for a safe and effective topical treatment in eczema. We expect to file an Investigational New Drug Application for MRX-6 in 2014, as well as run additional supportive trials in atopic dermatitis."
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers."
Windhover's Top Projects to Watch are hand-picked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. Many presenting companies in previous years have gone on to establish major partnerships.
About MFAIDs (Multi-Functional, Anti-Inflammatory Drugs)
Celsus Therapeutics is developing a platform of first-in-class, synthetic, non-steroidal anti-inflammatory drugs. They are designed to inhibit extracellular secretory phospholipase A2 (sPLA2), a catalytic enzyme responsible for initiating the inflammatory cascade through the production of arachidonic acid from membrane-associated phospholipids, specifically at the cell surface. MFAIDs can inhibit all sPLA2 isomers without disrupting cytoplasmic phospholipase A2 (cPLA2), a crucial homeostatic enzyme within cells. MFAIDS also enrich cell surface glycosaminoglycans, protecting cells from exposure to oxygen radicals and certain cytokines
About MRX-6 – Dermatitis
MRX-6 is an MFAID topical cream treatment under development for treating skin inflammatory disorders, specifically allergic contact dermatitis and atopic dermatitis, also known as eczema. ACD and atopic dermatitis usually caused by environment allergens.
About Celsus Therapeutics Plc.
Celsus Therapeutics is an emerging clinical stage company focused on the development of a new class of non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs or MFAIDs. Celsus's MFAIDs represent a new therapeutic platform for the treatment of a broad array of inflammatory diseases, such as allergies and autoimmune diseases. Presently, the Company has two lead drug candidates in its clinical pipeline, MRX-6, a topical cream for contact dermatitis and MRX-4, a nasal spray for treating allergic rhinitis (hay fever). Other potential treatments in preclinical development include OPX-1 for ocular inflammation, CFX-1 for cystic fibrosis, and MRX-5 for inflammatory bowel disease.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. http://www.elsevierbi.com/
FORWARD-LOOKING STATEMENTS – This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 20-F discusses some of the important risk factors that may affect our business, results of operations and financial condition. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.